TB Archives – Page 22 of 48 – Treatment Action Group

The Tuberculosis Treatment Pipeline

July 18, 2019
Chad Cipiti

Updates to this chapter can be found in the postscript at the end of this page. Original Report July 2012 By Erica Lessem Introduction Tuberculosis (TB) persists as a global health problem, suffering from both insufficient funding and political will.…

TB LAM Testing Briefs, 2019

April 10, 2019
Chad Cipiti

April 10, 2019 – Tuberculosis (TB) is the number-one killer of people living with HIV. Using TB lipoarabinomannan (LAM) tests, an inexpensive, urine-based test, has been proven to decrease mortality rates and allow for earlier diagnosis among people living with…

Mark Harrington Senate Briefing Transcript, 3-28-19

March 28, 2019
Chad Cipiti

TAG’s executive director Mark Harrington spoke at the U.S. Senate briefing held on March 28, 2019, not long after World TB Day. He invoked the stories of leaders that had tuberculosis, such as Eleanor Roosevelt and Nelson Mandela, on the…

Treatment Action Group Statement on the President’s Fiscal Year 2020 Budget Proposal

March 13, 2019
Chad Cipiti

Treatment Action Group (TAG) opposes the President's FY 2020 budget proposal, which makes a mockery of the administration's purported strategy to end AIDS in the United States over the next decade.

Statement from Treatment Action Group on FDA Priority Review of TB Alliance’s New Anti-TB Drug Pretomanid

March 11, 2019
Chad Cipiti

Treatment Action Group (TAG) welcomes the exciting news of a novel tuberculosis (TB) drug entering priority review by the Food and Drug Administration (FDA). Pretomanid represents only the fourth new TB drug to go through stringent regulatory review in the past half a century, and the first developed by a not-for-profit organization.

Closing the Gap in Tuberculosis Research and Development Funding Briefs

February 20, 2019
Chad Cipiti

In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.

Public Comment on NIDA Strategic Plan for Research at the Intersection of HIV/AIDS and Substance Use, Misuse, and Addiction

January 25, 2019
Chad Cipiti

TAG recently submitted a public comment to the National Institute on Drug Abuse (NIDA) at the National Institute of Health to inform a strategic plan it is developing to support research at the intersection of HIV and drug use.

Good COPs or Bad COPs 2.0: Advocacy to Ensure the Prioritization of TB in 2019 PEPFAR Country Operational Plans

January 23, 2019
Chad Cipiti

Good COPs or Bad COPs 2.0: Advocacy to Ensure the Prioritization of TB in 2019 PEPFAR Country Operational Plans (COPs) Every year, PEPFAR meets to discuss their strategy and budget for the following year, and set targets on implementing country operation plans…

Public Comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions

January 22, 2019
Chad Cipiti

TAG recently submitted this public comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions, highlighting the need to mitigate national supply challenges and shortages of critical TB drugs.

MDR-TB Treatment Guideline Communication from NYC DOHMH

January 11, 2019
Chad Cipiti

On January 11, 2019, TB Project Co-Director Lindsay McKenna attended a half-day conference hosted by the NYC Bureau of Tuberculosis Control. The recommendations from the conference are included in the NYC Department of Health and Mental Hygiene’s press release on the event, which you can download below.